Tech Company Financing Transactions
Aureka Biotechnologies Funding Round
On 8/11/2026, Aureka Biotechnologies raised financing from Granite Asia, HighLight Capital and Matrix Partners.
Transaction Overview
Company Name
Announced On
8/11/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to direct proceeds primarily toward research and large-scale training of its biological foundation models, as well as upgrade Lab-in-the-Loop, its experiment-centered feedback engine.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
23181 Verdugo Drive 106
Laguna Hills, CA 92653
USA
Laguna Hills, CA 92653
USA
Phone
Undisclosed
Website
Email Address
Overview
We envision a future where therapeutic discovery and development are digitalized, democratized, and ultimately decentralized. The existing pharmaceutical industry model is faltering and unsustainable, burdened by inefficiencies and high costs that result in patient and public distress. Aureka leads pharmaceutical transformation with a cutting-edge discovery platform that digitalizes therapeutic design at scale. Our aim is to significantly reduce cost and time for therapeutic discovery, enabling novel treatments for previously difficult targets and mechanisms.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Weian Zhao
Browse more venture capital transactions:
Prev: 8/10/2026: Global AI venture capital transaction
Next: 8/11/2026: AMDB Security Pro venture capital transaction
Share this article
News on VC Transactions
We report on funding rounds that are announced publicly. VC transactions reported here come from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs